Berkeley Lights, Inc. announced Curia's adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities. The Beacon system workflow at Curia leverages its proprietary Pentamice® platform, CHO-GSN? and TunaCHO?
platforms, as well as the company's antibody and cell-line engineering systems. The Pentamice® platform, CHO-GSN? and TunaCHO? platforms were developed at LakePharma, which Curia acquired in 2021.
Learn more at curiaglobal.com/beacon. With the addition of the Beacon system, Curia is able to provide a seamless and comprehensive portfolio of technologies and experience for rapid progression of client antibody programs. Its solutions address the earliest stage of discovery, through maturation and development, to manufacture of drug substance and final drug products under GMP. Curia scientists evaluated a variety of technologies and selected the Beacon system based on its proven capabilities and seamless integration in Curia's end-to-end manufacturing value chain.
With its abilities to deliver against a range of targets that fail with traditional technologies, combined with the proven immunological diversity inherent in its PentaMice® platform, Curia expects to deliver unique and diverse antibody sequences with comprehensive data analysis under timelines that are weeks in duration rather than months, and development candidates in six months or fewer.